Journal of Pain and Symptom Management
Volume 35, Issue 5 , Pages 563-567, May 2008

Opioids for Cancer Breakthrough Pain: A Pilot Study Reporting Patient Assessment of Time to Meaningful Pain Relief

  • Giovambattista Zeppetella, FRCP

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Giovambattista Zeppetella, FRCP, St. Clare Hospice, Hastingwood Road, Hastingwood, Essex CM17 9JX, United Kingdom.

St. Clare Hospice, Hastingwood; and Princess Alexandra NHS Trust, Harlow, United Kingdom

Accepted 29 June 2007. published online 13 February 2008.

Abstract 

Breakthrough pain is a common and distinct component of cancer pain that is usually managed with normal release opioids (also known as rescue medication) either before or soon after its onset. A prospective survey of hospice inpatients with breakthrough pain was undertaken to characterize their pain and then compare the time to onset of pain relief of their rescue medication. Patients presented with, on average, 1.7 different types of breakthrough pains (range, 1–4). The average number of breakthrough pains was four per day (range, 1–8), and the average duration of breakthrough pain was 35minutes (range, 15–60); most occurred suddenly and unpredictably. Patients used morphine, oxycodone, hydromorphone, methadone, or oral transmucosal fentanyl citrate as rescue medication and the average time to meaningful pain relief following their administration was 31minutes (range, 5–75). No difference was found between morphine, oxycodone, and hydromorphone. Methadone appeared to work faster than morphine (P<0.01) but no faster than oxycodone or hydromorphone, whereas oral transmucosal fentanyl citrate worked faster than morphine, oxycodone, hydromorphone, and methadone (P<0.001).

Key Words: Breakthrough pain, cancer, rescue medication, opioids

 

PII: S0885-3924(07)00750-6

doi:10.1016/j.jpainsymman.2007.06.012

Journal of Pain and Symptom Management
Volume 35, Issue 5 , Pages 563-567, May 2008